CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab.
B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment.
Ifthikharuddin
J J
JJ
Department of Hematology-Oncology, University of Rochester, Strong Memorial Hospital, Rochester, New York 14642, USA. j.j_ifthikharuddin@urmc.rochester.edu
Mieles
L A
LA
Rosenblatt
J D
JD
Ryan
C K
CK
Sahasrabudhe
D M
DM
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000097:blood*; D002648:Child; D005260:Female; D004854:Herpesvirus 4, Human / Q000235:genetics; D006801:Humans; D007223:Infant; D007421:Intestine, Small / Q000637:transplantation; D016031:Liver Transplantation / Q000009:adverse effects; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000209:etiology / Q000821:virology; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000209:etiology* / Q000821:virology; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects*; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology; D012333:RNA, Messenger / Q000097:blood; D000069283:Rituximab; D013997:Time Factors
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D012333:RNA, Messenger; D000069283:Rituximab